title: Effect of long-term treatment with beta-blocker on cardiac hypertrophy in SHR.
abstract: Recent studies suggest that beta-blocker treatment may attenuate cardiac hypertrophy induced by pressure overload in the spontaneously hypertensive rat (SHR), but the effect of this therapy on the reconstitution of the intracellular constituents in the heart that occurs during the development of cardiac hypertrophy has not been examined. In this study, we investigated the effect of chronic administration of carteolol (4 mg/kg/day p.o.) or propranolol (20 mg/kg/day p.o.), beta-blockers with distinct modes of action, on the composition of cardiac myosin isozymes and histological findings as well as heart weight. Therapeutic periods were 4, 12 or 30 weeks. Though blood pressure was not significantly reduced, the development of cardiac hypertrophy was suppressed as evidenced by left ventricular weight in both groups of carteolol- and propranolol-treated SHR for all therapeutic periods. Again, beta-blocker treatment for 12 weeks alleviated myocardial degeneration and reactive fibrosis which were observed in all cases of age-matched untreated SHR. However the extent of the transition of cardiac myosin isozymes from V1 to V2 or V3 were essentially the same among all groups including untreated SHR. These results indicate that chronic administration of beta-blockers attenuates the development of cardiac hypertrophy and degeneration without affecting the transition of myosin isozymes which is thought to be a kind of biochemical adaptation of the myocardium to overload.
authors.affiliation: Third Department of Internal Medicine, University of Tokyo, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Ieki
authors.forename: Y
authors.initials: Y
authors.lastname: Yazaki
authors.forename: K
authors.initials: K
authors.lastname: Yamaoki
authors.forename: H
authors.initials: H
authors.lastname: Tsuchimochi
authors.forename: M
authors.initials: M
authors.lastname: Yoshizumi
authors.forename: I
authors.initials: I
authors.lastname: Komuro
authors.forename: T
authors.initials: T
authors.lastname: Sugiyama
authors.forename: Y
authors.initials: Y
authors.lastname: Seko
authors.forename: F
authors.initials: F
authors.lastname: Takaku
authors.forename: M
authors.initials: M
authors.lastname: Kojima
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000818:Animals; D006332:Cardiomegaly / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002354:Carteolol / Q000494:pharmacology; D006909:Hydroxyproline / Q000378:metabolism; D008297:Male; D009218:Myosins / Q000378:metabolism; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D013997:Time Factors
chemical_list: D000319:Adrenergic beta-Antagonists; D002354:Carteolol; D011433:Propranolol; D009218:Myosins; D006909:Hydroxyproline